B-288 The Beginning of the End: AGO2 Protein Identified and Validated as a Novel Biomarker for Multi-cancer Diagnosis Through Bioinformatics Analysis and Immunoassay

Hashmi, A; Hutvagner, G; Sidhu, S

B-288 The Beginning of the End: AGO2 Protein Identified and Validated as a Novel Biomarker for Multi-cancer Diagnosis Through Bioinformatics Analysis and Immunoassay

Hashmi, A Hutvagner, G

Sidhu, S

Permalink

Publisher:: Oxford University Press (OUP)
Publication Type:: Journal Article
Citation:: Clinical Chemistry, 2023, 69, (Supplement_1), pp. hvad097.608
Issue Date:: 2023-09-27

Closed Access

	Filename	Description	Size
	hvad097.608.pdf	Published version	73.88 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Hashmi, A
dc.contributor.author	Hutvagner, G https://orcid.org/0000-0002-7231-9446
dc.contributor.author	Sidhu, S
dc.date.accessioned	2024-04-06T00:44:43Z
dc.date.available	2024-04-06T00:44:43Z
dc.date.issued	2023-09-27
dc.identifier.citation	Clinical Chemistry, 2023, 69, (Supplement_1), pp. hvad097.608
dc.identifier.issn	0009-9147
dc.identifier.issn	1530-8561
dc.identifier.uri	http://hdl.handle.net/10453/177508
dc.description.abstract	Abstract Background Despite significant progress in cancer research the complexity and heterogeneity of the disease still pose major challenges to accurate diagnosis and effective treatment Recent advancements in biomedical technologies have led to the identification of reliable potential cancer biomarkers In this sense the link between microRNAs master regulators of gene expression cancer is well established but there has been little research on the microRNA machinery itself We aim to investigate whether changes in the expression of genes proteins involved in the miRNA pathway can be used for multi cancer detection Method We analyzed RNASeq data from the TCGA The Cancer Genome Atlas and GTEX The Genotype Tissue Expression projects to compare the expression of core components in the miRNA biogenesis pathway including AGO2 DGCR8 XPO5 RAN DROSHA DICER and TARBP2 in normal and tumorous samples across 22 tissue types including adrenocortical AML breast colon lung liver esophageal prostate pancreas stomach thyroid rectum uterus and ovarian cancer We accessed and analyzed the TCGA and GTEx datasets using the UCSC Xena Browser We also measured the protein concentrations of all these microRNA regulators in 15 normal adrenal cortex 15 benign adenoma and 15 adrenocortical cancer tissue homogenate samples using commercial ELISA kits The Human Protein Argonaute 2 EIF2C2 ELISA Kit AE45910HU Abebio Co Ltd was used for the assay procedure which was performed according to the manufacturer s instructions Statistical analysis was performed using GraphPad Prism Version 9 GraphPad Software CA USA A P value of less than 0 05 was considered statistically significant Results Our RNASeq analysis results showed that among all microRNA regulators AGO2 is most highly significantly over expressed in samples derived from cancer patients compared with normal controls P 0 05 In addition we analysed the protein expression of AGO2 in adrenocortical tissue homogenate samples Our results demonstrated
dc.language	en
dc.publisher	Oxford University Press (OUP)
dc.relation.ispartof	Clinical Chemistry
dc.relation.isbasedon	10.1093/clinchem/hvad097.608
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1004 Medical Biotechnology, 1101 Medical Biochemistry and Metabolomics, 1103 Clinical Sciences
dc.subject.classification	General Clinical Medicine
dc.subject.classification	3202 Clinical sciences
dc.subject.classification	3205 Medical biochemistry and metabolomics
dc.title	B-288 The Beginning of the End: AGO2 Protein Identified and Validated as a Novel Biomarker for Multi-cancer Diagnosis Through Bioinformatics Analysis and Immunoassay
dc.type	Journal Article
utslib.citation.volume	69
utslib.for	1004 Medical Biotechnology
utslib.for	1101 Medical Biochemistry and Metabolomics
utslib.for	1103 Clinical Sciences
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	University of Technology Sydney/Strength - CHT - Health Technologies
pubs.organisational-group	University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
utslib.copyright.status	closed_access	*
pubs.consider-herdc	true
dc.date.updated	2024-04-06T00:44:41Z
pubs.issue	Supplement_1
pubs.publication-status	Published
pubs.volume	69
utslib.citation.issue	Supplement_1

Abstract:

Abstract Background Despite significant progress in cancer research the complexity and heterogeneity of the disease still pose major challenges to accurate diagnosis and effective treatment Recent advancements in biomedical technologies have led to the identification of reliable potential cancer biomarkers In this sense the link between microRNAs master regulators of gene expression cancer is well established but there has been little research on the microRNA machinery itself We aim to investigate whether changes in the expression of genes proteins involved in the miRNA pathway can be used for multi cancer detection Method We analyzed RNASeq data from the TCGA The Cancer Genome Atlas and GTEX The Genotype Tissue Expression projects to compare the expression of core components in the miRNA biogenesis pathway including AGO2 DGCR8 XPO5 RAN DROSHA DICER and TARBP2 in normal and tumorous samples across 22 tissue types including adrenocortical AML breast colon lung liver esophageal prostate pancreas stomach thyroid rectum uterus and ovarian cancer We accessed and analyzed the TCGA and GTEx datasets using the UCSC Xena Browser We also measured the protein concentrations of all these microRNA regulators in 15 normal adrenal cortex 15 benign adenoma and 15 adrenocortical cancer tissue homogenate samples using commercial ELISA kits The Human Protein Argonaute 2 EIF2C2 ELISA Kit AE45910HU Abebio Co Ltd was used for the assay procedure which was performed according to the manufacturer s instructions Statistical analysis was performed using GraphPad Prism Version 9 GraphPad Software CA USA A P value of less than 0 05 was considered statistically significant Results Our RNASeq analysis results showed that among all microRNA regulators AGO2 is most highly significantly over expressed in samples derived from cancer patients compared with normal controls P 0 05 In addition we analysed the protein expression of AGO2 in adrenocortical tissue homogenate samples Our results demonstrated

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/177508